Kamelia Zerrouki

机构：AstraZeneca (Australia), AstraZeneca (Canada)

发表论文 13 篇 · 总被引 860 次 · h-index 5

代表论文

• IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE (2018 · Nature Communications · 被引 590)
• Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus (2018 · Lupus Science & Medicine · 被引 150)
• Targeting p16-induced senescence prevents cigarette smoke-induced emphysema by promoting IGF1/Akt1 signaling in mice (2019 · Communications Biology · 被引 67)
• Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus (2020 · Scientific Reports · 被引 26)
• Shared and Distinctive Transcriptomic and Proteomic Pathways in Adult and Juvenile Dermatomyositis (2023 · Arthritis & Rheumatology · 被引 20)
• FLT3L neutralization reduces dendritic cell numbers, T Cell activation, and salivary gland lymphocyte infiltration in the NOD.H2h4 Sjögren’s mouse model (2025 · The Journal of Immunology · 被引 2)